Family Site

The contents provided by this page are intended only for Australian healthcare professionals.
Please leave this site if you are not an Australian healthcare professional.

Indications Dosing Administration Device Safety Information

Indications

Indications and posology1

Remsima® SC is indicated for adult patients.

Indication Posology Special dosing instructions
Moderately to severely active or fistulising, active
Crohn’s Disease

IV induction with 5 mg/kg at week 0,2

SC maintenance with 120 mg dose every 2 weeks, starting from Week 6

Moderately to severely active
Ulcerative Colitis
Severe, active
Ankylosing Spondylitis
Active and progressive
Psoriatic Arthritis

In combination with MTX

Or alone in patients with intolerance or contraindications to MTX

Moderate to severe
Plaque Psoriasis
Moderately to severely active
Rheumatoid Arthritis

IV induction with 3 mg/kg at Week 0,2

SC maintenance with 120 mg dose every 2 weeks, starting from Week 6

Must be given concomitantly with MTX

* For subcutaneous injection, 120mg is fixed dose for all indications.

References

1. Remsima® Summary of Product Characteristics. Available at: https://www.ema.europa.eu/en/documents/product-information/Remsima®-epar-product-information_en.pdf Accessed 4 Sep 2020.

Abbreviations

IV, intravenous; MTX, methotrexate; SC, subcutaneous